Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04590820
Title Oral Tazemetostat in Combination With Rituximab in R/R FL
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Swedish Medical Center
Indications

follicular lymphoma

Therapies

Rituximab + Tazemetostat

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Swedish Cancer Institute Edmonds Campus Edmonds Washington 98026 United States Details
Swedish Cancer Institute Issaquah Campus Issaquah Washington 98029 United States Details
Swedish Medical Center Cancer Institute - First Hill Seattle Washington 98104 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field